Monday, 3 October 2016

Jai Hind to Jatropha: CSIR Fuels Research on Biodiesel Production

Jai Hind to Jatropha
CSIR Fuels Research on Biodiesel Production
{Feature has been uploaded by CSIR (Unit for Science Dissemination), Ministry of Science & Technology, New Delhi}
Nature has it all. Whether it is food, fibre, fuel or a drug formulation, Nature has an answer to all our needs. It is only the judicious use of the myriad gifts of Nature that is important for our sustenance and well-being. Alas, it does not always happen. Take for example the Earth’s rich reserves of petroleum: a product of ancient biomass transformed, over geological time, under high temperature and pressure. The increasing use of these fossil fuels the world over today grimly reminds us of the fact that the finite reserves of such fuels may exhaust sooner than later. Besides, oil extraction and refining procedures are costly. Reflected in the rising price of petrol and diesel, the challenge of excessive demand of these fuels over their limited supply has today severely hit the country’s economy.
The solution to the challenge of depleting natural reserves of oil has come from Nature again. Thanks to the naturally gifted crop, Jatropha curcas, which is today well recognized as the source for producing biofuel that is significantly cheaper than crude oil. Although a native to Central America, Jatropha is a small tree of Euphorbiaceae family that today grows in many tropical and subtropical areas, including India, Africa, and North America. The mature trees bear separate male and female flowers. Fruits are ovoid in shape and the seeds on maturation are dried before oil extracton.
The prime ingredient in the manufacture of biodiesel is vegetable oil like sunflower, soya or peanut oil. But as these oils are edible and expensive, they are not used for bio-diesel production. On the other hand, Jatropha produces oil-rich seeds from which oil can be easily extracted and processed for producing bio-diesel. The seeds contain about 30-35% of oil. Amazingly, Jatropha may yield more than four times as much fuel per hectare as soybean and more than ten times than that produced by maize. Moreover, as Jatropha contains several toxic compounds, such as lectin, saponin, carcinogenic phorbol, and a trypsin inhibitor, its untreated seeds are not fit for human consumption. As Jatropha oil burns with a clear smokeless flame, it can also be used as a kerosene substitute.
Jatropha is a hardy plant that is resistant to drought and pests. Moreover, it can be grown in soils having low fertility, although crop yield can be enhanced using fertilizers containing magnesium, sulphur, and calcium. The yield of seeds from Jatropha cultivation can range from 1,500 to 2,000 kilograms per hectare that corresponds to extractable oil yield of about 540 to 680 litres per hectare. The remaining press cake of jatropha seeds after oil extraction can also be used for energy production. The processed oil from Jatropha seeds can be used in compression-ignition (diesel) engines. It can also be blended with conventional diesel to avoid the need for engine modification. The process of converting vegetable oil into biodiesel fuel is called ‘transesterification’. An important by-product of biodiesel refinement is glycerol.

The National Botanical Research Institute (NBRI), Lucknow is a forerunner in biodiesel and other hydrocarbon plants research. The focus on harvesting energy from biomass began with the initiative of Prof. T. N. Khoshoo, who encouraged scientists to initiate collection of germplasm. Dr. H. M. Behl, who had done extensive work on guayule (Parthenium argentatum) joined this Project. Under the guidance of Dr. P. Pushpangadan, former Director, NBRI, the team ventured further in harnessing the potential of oil crops for production of biofuels.
NBRI scientists have developed protocols for extraction of oil from the seeds of Jatropha curcas, Madhuca indica, Salvadora species and Pongamia pinnata for use as biodiesel. The extracted oil is transesterified and tested as biodiesel. It is tested for use in stationery motors as well as for automobiles. The oil is also processed for removal of gums, free fatty acids, water and other suspended or solid particles.
For screening the germplasm of this oil crop, NBRI scientists collected the seeds of Jatropha curcas and Pongamia pinnata from various parts of the country and evaluated them for their morphological traits, oil quantity and quality using specialized techniques. Nursery experiments such as inoculation with microbes, hardening of the saplings for long distance transportation and raising healthy plants have also been attempted.
Production of biofuels holds enormous potential for farmers, as the basic source of such fuels is crops. This would help farmers to not only grow their income but also generate their own supply of affordable energy, thus boosting rural economy. As biofuels produce fewer emission of carbon monoxide and toxic chemicals that cause vehicular pollution, they are called ‘green fuels’ that are a safer option to petrol and diesel, while having a potential to lower global warming. Moreover, biofuels would reduce the burden of importing huge quantity of crude oil. Undoubtedly, production of biofuels is poised to benefit one and all.
The oil from Jatropha curcas seeds is used for making biodiesel fuel in Philippines and in Brazil. Jatropha oil is being promoted as an easily grown biofuel crop in many countries including India. Interestingly, the first successful trial run of passenger trains on 5% biodiesel was conducted in 2003 with the Delhi-Amritsar Shatabdi Express with a 4000 HP engine. Southern Railways, at its Perambur Loco Works Laboratory, Chennai, has set-up a pilot plant for biodiesel production and has been using 5% biodiesel in some of its locomotives since July 2004. The railway line between Mumbai and Delhi is planted with Jatropha and the train itself runs on 15-20% biodiesel.
It is also a heartening fact that biofuels have also been tested as a substitute to aviation fuels.  Air New Zealand successfully completed a test flight in 2008 from Auckland using a 50/50 mixture of jatropha oil -derived biofuel and Jet engine fuel, while in a similar feat in early 2009, Continental Airlines completed such a successful two-hour test flight, signifying the importance of cheaper, environment-friendly alternatives to fossil fuels.

CSIR Makes Headway in Nanotechnology:Gold Nanoparticles for Novel Drug Delivery

CSIR Makes Headway in Nanotechnology –
Gold Nanoparticles for Novel Drug Delivery

 {Feature has been uploaded by CSIR (Unit for Science Dissemination), Ministry of Science & Technology, New Delhi}

Enter the world of fantasy – the realm of nanoworld – and you will find structures with dimensions about the size of atoms, which are the building blocks of all matter existing in Nature. The study and design of such structures, measuring in the scale of nanometre or one-billionth of a metre is what nanotechnology is all about. The sheer size of nanostructures is the hallmark of the astounding applications of nanotechnology in diverse fields.
            In the field of Medicine, the unimaginably vast potential of nanotechnology has opened up the possibility of designing nanostructures for both diagnosing the diseased tissues and delivering drugs and other therapeutic substances to target areas in the human body. It is a matter of pride that CSIR scientists have made a significant headway in designing nanoparticles of gold for delivering drugs to specific body cells. Interestingly, these nanoparticles are covered with stabilizing agents that prevent their aggregation and also help the nanoparticles survive in both alkaline and acid media. Gold is chosen for designing these nanoparticles primarily because of its non-toxic nature, convenient synthesis in a variety of sizes, and ability to attach payloads through various means like electrostatic, covalent or non-covalent interactions.
Thanks to Dr. B. L. V. Prasad, Scientist, Physical and Materials Chemistry Division of National Chemical Laboratory (NCL), Pune and his team who have made painstaking efforts in exploring several biochemical substances that could act as nanoparticle stabilizing agents, which also enhance the functional role of the nanoparticle in carrying the drug and delivering the therapeutic molecules to target cells. It was found that Gellan gum, widely used in food and confectionary industry as thickening and gelling agent, could be used as nanoparticle stabilizing agent, for it has unique structural features. Gellan gum comprises four linked monosaccharides or simple sugars, including one molecule of rhamnose (a sugar found in various plants), one molecule of glucuronic acid (an oxidized glucose molecule), and two molecules of glucose. It is, therefore, a high molecular weight polysaccharide gum.
Gellan gum is produced by culture fermentation of a carbohydrate by the microbe Pseudomonas elodea, which is an aerobic, non-pathogenic, gram-negative bacterium. This water soluble gum having thickening, gelling and stabilizing properties is commercially available and is approved for food, cosmetic and pharmaceutical use in many countries. It has also been an ingredient of hair care products, creams and sunscreens among other such products.  According to Dr. Varsha Pokharkar from Poona College of Pharmacy, Bharati Vidyapeeth University, Pune, who has also contributed to this work, the reducing and stabilizing properties of this gum have been crucial for using it in the synthesis of gold nanoparticles.
 Nanoparticles stabilized with gellan gum also display superior stability to pH changes. Such nanoparticles have been used to load one of the anthracycline rings with antibiotic, Doxorubicin hydrochloride, and tested for their cytotoxic effects against human glioma (brain tumor) cell lines, namely, LN-18 and LN-229.
Dr. Anjali Shiras from National Centre for Cell Science (NCCS), where the activity of nanoparticles on these cells was assessed, says that the drug loaded on nanoparticles show enhanced cytotoxic effect as compared to pure drug taken at same concentrations as present on the nanoparticle surface, while being effective for a longer period of time.
Normally, anti-cancer drugs targeted at brain tumors face the challenge of crossing the Blood Brain Barrier (BBB) that blocks the drug delivery to the tumor site. On the other hand, nanoparticles have been shown to cross this barrier, which is why such drug delivery systems are a better alternative to delivering drugs in tissues of the brain. In this context, gum loaded nanoparticles having many sugar moieties could have an additional advantage as the BBB contains glucose receptors.
           
            Another exciting application of gold nanoparticles is to counter the challenge of multi-drug resistant microorganisms which develop immunity against certain drugs due to their prolonged and excessive use. According to Dr Pankaj Poddar of NCL, Pune, dressing up or capping nanoparticles with antibiotics has worked well. Dr Poddar and his colleagues used cephalexin, a broad-spectrum betalactam antibiotic, for the in situ reduction and capping of gold nanoparticles. Gold nanoparticles have been successful on certain drugs, and research efforts are on for loading some more medicines onto gold nanoparticles for their effective delivery to target body cells. The glittering gold, treasured by us all for its beauty and monetary value, thus has an exciting facet of its usage in delivering medicines effectively.
            The controlled synthesis of nanoparticles is surely an extremely important area of nanotechnology.  In fact, exquisite inorganic nano-scale structures are naturally produced by microorganisms like magnetite particles in magnetotactic bacteria and amorphous silica exoskeletons of diatoms. In an NCL collaboration involving Dr Murali Sastry (Materials Chemistry Division), Dr Rajiv Kumar (Catalysis Division), Dr Absar Ahmad and Dr Islam Khan (Biochemical Sciences Division) has demonstrated the synthesis of silver and gold nanoparticles within the cells of a fungus, Verticillium. The scientists found that treatment of the fungal biomass with aqueous ions of gold chloride resulted in reduction of the metal ions, resulting in intra-cellular formation of gold nanoparticles. As these gold nanoparticles are formed, the fungal biomass dramatically turns purple in colour.
            It is quite exciting that fungi, which are eukaryotic organisms, can be used in nano-synthesis. As fungi are also good sources of enzymes, the enzymatic processes leading to the synthesis of advanced nano-materials have the potential for scale-up. The NCL group has demonstrated that different genera of fungi can be used to synthesize nanoparticles having different chemical compositions.
            In yet another development in nanotechnology, NCL Scientists have shown the biological synthesis of triangular gold nanoprisms. The properties of a metal nanoparticle can be tailored by controlling its size, shape, composition and crystallization. Specific chemicals such as polypeptides secreted by bacteria, namely, Escherichia coli, have been shown to induce the growth of flat, triangular gold nanocrystals at a four per cent yield relative to the total nanoparticle formation. Dr. Murali Sastry of Physical & Materials Chemistry Division, Dr. Absar Ahmed of Biochemical Sciences Division and the team at NCL have demonstrated biological synthesis of large amounts of triangular gold nanoprisms by a single-step, room-temperature reduction of gold salt solution by the extract of the plant, lemongrass (Cymbopogon flexuosus).
            The lemongrass extract on mixing with gold salt solution exhibits a change of colour from pale yellow to a vivid ruby red. The reaction mixture is allowed to stand for six hours to yield a large number of triangular gold nanoparticles of 8 – 18 nm thickness with an edge length of 200-500 nm. This method has reported a yield of 45 per cent. The scientists also enhanced the percentage of gold nanotriangles in the reaction medium up to 95 per cent of the nanoparticle population by repeated centrifugation.
            In fact, Nature has already set the rules for us as it has created innumerable nanostructures each being a masterpiece entity in itself. All we have to do is to understand the secrets of Nature for designing our own nanostructures with unique properties that suit our myriad needs.


LaCONES: CSIR Takes Steps for Nurturing Nature

 LaCONESCSIR Takes Steps for Nurturing Nature

{Feature has been uploaded by CSIR (Unit for Science Dissemination), Ministry of Science & Technology, New Delhi}

What happens when our precious possessions are lost? Invariably, loss of wealth or something dear makes most of us quite upset that triggers us to take measures for protecting our belongings. Well, Nature too belongs to all of us. The bountiful Nature is replete with priceless possessions in the form of myriad varieties of life forms, each one of them being a masterpiece in itself. But alas, some of them like the Caspian tiger, Sea cow, Dodo, Quagga and many more are gone forever and we shall never see them again. With their extinction, the millions of years that these species took to evolve are also lost. Surely, loss of this natural wealth reflected by extinction of several plant and animal species from the face of the Earth is not only very disturbing but also is a fair reason for gearing up our action to conserve the endangered life forms that are on the verge of extinction.  
Needless to say, conservation of the existing biodiversity is the need of the hour. Several factors like destruction of forests and indiscriminate killing of animals as a sport and for trade has been the major cause for pushing animals to extinction.  It is a matter of pride that CSIR has taken a lead in conservation of wildlife as the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, initiated in 1998 the setting up of the laboratory for Conservation of Endangered Species (LaCONES) with help of the Department of Biotechnology (DBT), Government of India, New Delhi and the Central Zoo Authority (CZA), New Delhi. The Department of Forestry, Government of Andhra Pradesh and the Nehru Zoological Park at Hyderabad, are also major partners in this joint venture.
Piloted by Dr. Lalji Singh, former Director, CCMB and Dr. S. Shivaji, Director-grade scientist, CCMB, LaCONES is a unique laboratory set up at Attapur near Nehru Zoological park, Hyderabad, on land allotted by the Government of Andhra Pradesh. This novel scientific endeavour is a part of a national programme to tackle the challenge of wildlife extinction by employing novel methods of biotechnology and assisted reproductive technologies. The idea is to conserve and prevent the extinction of endangered wildlife by focusing on both conservation as well as propagation of such species by several innovative techniques. It was on February 1, 2007 that the then President of India, Dr A. P. J. Abdul Kalam dedicated the LaCONES to the Nation for the cause of conservation of wildlife (CSIR News, Vol. 57, No. 4, 28 February 2007)
The wide range of research activities at the LaCONES includes the resurrection of extinct and endangered species by cloning the frozen genetic material and using oocytes of a closely related species as surrogate mother, monitoring of genetic variations and establishing of gene and cell banks for such species. A major focus is on the development of assisted reproduction technologies such as intrauterine insemination, in vitro fertilization, intra-cytoplasm sperm injection, embryo transfer, etc., for conservation of rare species.
The state-of-the-art LaCONES has facilities for cryo-preservation of semen, eggs and embryos of endangered species. Semen analysis is done to study the semen quality for selecting animals for breeding. Besides, standardization of artificial insemination for wild animals is another major activity at LaCONES. Planned in-house breeding strategies or captive breeding of animals that cannot be saved in the wild are developed. The outcome of such efforts has greatly helped in preventing extinction of wild animals like cheetah, non-human primates, and several birds among other rare species.
Protocols have been established for anaesthetizing and electro-ejaculating a wide range of animals such as lions, tigers, leopards, hyenas, jackals, bears, deers and monkeys. A mobile van equipped with facilities like cryopreservation, sonography, computerized sperm motility analyzer. etc., enables the scientists to reach different  habitats for collecting samples.
As DNA is the blueprint of life of all organisms, its long-term preservation is a crucial step in storing all information about various specifications of that life form. This has a futuristic possibility of reconstructing an extinct species, while providing a renewable resource for genetic variation in endangered species through captive breeding when loss of variation through inbreeding seriously threatens their survival. On the contrary, if the DNA and cells of endangered species were not stored, the vital information linked to these life forms would be lost forever. It is a heartening fact that the LaCONES has been honoured as a Member of the International Consortium of the Frozen Ark – an international depository of DNA representing the Indian subcontinent.
The Frozen Ark Consortium is a worldwide group of institutions, with its coordinating office located at the School of Biology, University of Nottingham, U.K. In the Frozen Ark freezers, the DNA and the viable cells of endangered species are stored in liquid nitrogen at -196oC. The CCMB scientists have developed primers to decode the molecular signatures of endangered species from their tissue samples by the technique of DNA fingerprinting. A database of molecular signatures of over 2000 animal species has been created.
Scientists at LaCONES have successfully employed the assisted reproductive technologies to propagate wildlife species such as black buck, chital and blue rock pigeon. The birth of ‘Spotty’, a baby spotted deer/cheetal, using artificial insemination in March 2006 was indeed breathtaking. Such a success story was repeated in August 2007 when ‘Blacky’, a black buck, was born to one of the three inseminated bucks. The same techniques are being employed on other rare species such as vultures, Nicobar pigeons and the big cats for increasing their dwindling numbers. The LaCONES is indeed a classic example of application of science & technology in protecting thousands of marvelous creations of Nature.


Genetic Diversity in Indian Populations

Genetic Diversity in Indian Populations

{Feature has been uploaded by CSIR (Unit for Science Dissemination), Ministry of Science & Technology, New Delhi}

A home to more than one billion people, India is a land of matchless diversity in diverse ways. With scores of culturally diverse communities inhabiting the nation, each portraying a different language, religion, set of customs and cuisine, India is not only ethnically distinct that is much apparent but the human populations of this country are also distinct at the level of genes the hereditary material that is passed on from one generation to the next thanks to novel findings of a joint team of Indian and American scientists, with key players from the Centre for Cellular and Molecular Biology (CSIR), Hyderabad, India and from Harvard Medical School, the Harvard School of Public Health and the Broad Institute of Harvard and MIT.
Interestingly, if we look at our genetic material that biochemically comprises the DNA molecule, any two unrelated individuals surprisingly differ just by 0.1%, as the remaining 99.9% of DNA is completely identical. What an irony then that all the amazing human diversity, at the level of genes, is housed only in this variable, and apparently tiny, portion of our DNA! It is this region of DNA, comprising some three million base pairs, that is a storehouse of clues to a rich source of information, and has today helped scientists to reconstruct the historical origins of human populations in India. It is also the region of our genetic material, which clearly points to the many genetic variations in human beings that make select individuals at a higher risk of certain diseases as compared to others.
For this study on ascertaining genetic variability across various human populations in India, about 5.6 lakh genetic markers were analyzed across the genomes of 132 individuals who were selected from 25 diverse groups in India that represented 13 states comprising all six language families, traditionally upper and lower castes, as well as tribal groups. An important revelation of this study led by Lalji Singh and David Reich, published in 24th September 2009 issue of Nature, is that different Indian groups carry genomic material from two distinct ancestral populations – the ‘Ancestral North Indians’ (ANI) who are related to western Eurasians, from whom the Indian populations have inherited 40-80 % of their ancestry and the rest from ‘Ancestral South Indians’ (ASI) who are not related to any group outside India. The ANI ancestry has been found to be significantly higher in Indo-European than Dravidian speakers, which suggests that populations descending from ASI may have spoken a Dravidian language before mixing with populations descending from ANI.
For analyzing the genetic markers, which are the regions of genetic variations occurring as single nucleotide polymorphisms (SNPs), the blood samples of select individuals of 25 diverse groups of India were collected. After DNA extraction from these samples, all DNA samples were genotyped on Affymetrix 6.0 arrays or DNA chips, and analyzed for genetic variations in 560,123 SNPs. Scientists then employed novel statistical approaches for studying the genetic variations in these individuals of diverse groups. Allele frequency differentiation among the groups as well as inbreeding in each group were assessed using sophisticated software. A novel toolkit has also been developed by scientists for understanding the relationships among population groups, thus tracing their history of origin.
This novel work has thus revealed, through modern genomic technology, that almost all Indian groups, including the traditional ‘tribes’ as well as ‘castes’, have descended from the mixtures of ANI and ASI ancestral populations. A significantly higher ANI ancestry has been found in traditionally upper castes than in middle/lower caste groups. According to CCMB scientists, it is impossible to distinguish castes from tribes using the data, which supports the view that castes grew directly out of tribal-like organizations during the formation of Indian society.
This study has also revealed that the Andamanese – a small population of indigenous people of the Andaman Islands – appear to be related exclusively to the Ancestral South Indian lineage and completely lack Ancestral North Indian ancestry. This surely opens a door to the history of the Ancestral South Indians who diverged from other Eurasians, probably tens of thousands of years ago. Genetic variation studies on tribal populations, who have been locked away from the modern world, is the key to unlock not only the mystery of our own origins but is also important for understanding the genetic basis of complex diseases. Many of the environmental risk factors related to modern lifestyles, such as intake of unhealthy diet and lack of physical exercise, which are at the crux for triggering many complex diseases, are usually uncommon in tribals. Therefore, with studies on primitive, isolated tribal populations, it would be possible to differentiate genetic factors from environmental risk factors for these diseases. In this direction, CCMB has undertaken a large project on studying the human genetic diversity in tribal and caste populations of India in collaboration with Anthropological Survey of India.
It has also come to light that the ancestry of many groups in modern India could be traced back to a small number of founding individuals, which explains why these groups have remained genetically isolated from other groups for thousands of years, with limited gene flow due to endogamy or marriages within the group. Such ‘founder events’, as they are popularly called, are the root cause of the exceptionally high incidence of some genetic diseases among only Indians. According to Lalji Singh, former director of CCMB and a Bhatnagar Fellow whose pioneering efforts in this field are commendable, India is genetically not a single large population, but comprises many smaller isolated populations that have descended from several founder events.
Just as founder events are known to increase the incidence of recessive genetic diseases in other human populations like Finns and Ashkenazi Jews, the same could most likely be the case for many groups in India, where inter-caste marriages are a taboo. According to researchers, the founder effects are responsible for an even higher burden of recessive diseases in India than consanguinity. According to researchers, this can be confirmed by carrying out a systematic survey of Indian groups for identifying the communities that have descended from the strongest founder events. This would help in pinning down the culprit genes responsible for causing many devastating genetic diseases, thus opening the door to finding effective therapies and providing appropriate clinical care to the affected individuals and those at risk.
The history of population structure in India, therefore, has its root in two ancestral populations — ANI and ASI — and it is the rampant mixture of these populations that is the hallmark of all the amazing genetic variations in many Indian groups. The concepts of ancestral genomic content, their mixture throughout India and importance of founder events have assumed significance, for these have serious implications on the health of the Indian populations. The scope of further research in this field would be to estimate a date when the mixture of these populations might have occurred. For this, a detailed study of the length of genetic stretches of ANI ancestry in Indian samples assumes importance. Another area of scientific interest is exploring the history of ANI and ASI populations before they began to be mixed.
India, the world's second most populous nation is uniquely distinct for its varied diversity. Be it geographic or climatic diversity, be it the diversity in languages, religions and cultures of its people, or be it the genetic diversity as evident today, after all it is our very diversity that imparts strength to our oneness.

Box 1

India Cracks the Human Genome (2009)


In a ground breaking work, CSIR scientists at the Institute of Genomics and Integrative Biology (IGIB), New Delhi, completed the first human genome sequencing in India in December 2009, setting the stage for India’s entry into individual genomics that opened up new possibilities in disease diagnostics and treatment. The sequenced genome was that of an anonymous healthy individual from Jharkhand. While the first human genome sequencing took over a decade, and a whopping 3 billion US dollars to complete the task, CSIR bagged the unique credit for accomplishing the same in only 45 days, spending Rs. 15 lakhs (US$ 30,000).
The IGIB scientists triumphantly generated over 51 gigabases of data, using the most sophisticated sequencing technology that enables massive parallel sequencing of millions of fragments of the genetic material, as small as comprising only 76 base pairs. These small DNA fragment once sequenced, are then mapped back to the reference genome. This herculean task of finding the sequence of the entire human genetic material, comprising three billion base pairs, was possible due to the CSIR supercomputing facility at IGIB. With this achievement, India became the sixth country after US, China, Korea, Canada and UK, to demonstrate the capability of sequencing and assembling a complete human genome.
Understandably, sequencing of the human genome requires high computational capability and technological know-how in handling sophisticated machines and analyzing huge volume of data. The first human genome sequencing initiative was conceived as early as 1984. In addition to the United States, the ‘International Human Genome Project Consortium’ comprised geneticists from United Kingdom, France, Germany, Japan and China. The International Human Genome Project formally started in 1990 and was completed in 2003, sequencing the genomes of Craig Venter, James Watson and an anonymous Chinese individual. CSIR could achieve this by adapting to new technologies and effectively integrating complex information technology tools with analytical capabilities.
The sequencing of the human genome would help us to understand the variations at genetic level that make two individuals different. More importantly, since there is an association between the genetic variants and predisposition to diseases, human genome sequencing would be enormously important in diagnosis and management of various diseases including cancer. Interestingly, the sequencing of the Indian genome has revealed a large number of hitherto unknown variations that include single nucleotide polymorphisms (SNPs) as well as many insertion/deletions in our genetic material. Understanding the functional role of these variations would, for sure, throw light on identifying the markers linked to specific diseases, which could be specifically hunted for predicting diseases before they spell disaster. 
Earlier, CSIR scientists also completed the genome sequencing of zebrafish an organism popularly used to model human diseases – that has half the size of the human genome. With this feat, India became the first country to sequence the wild type strain of zebrafish.

Box 2
Another Door Opened –
 Genetic Diversity Mapped in Asia

Housing 60% of the human inhabitants of planet Earth, Asia – the world's largest continent – is a huge melting pot of genetic diversity. The contributors of this exceedingly rich human resource are the scores of unknown ancestors who migrated from different parts of the world and settled down in this region over thousands of years.
Ancestral human populations are believed to have originally spread out from Africa, from where they slowly began to adapt different parts of the globe due to the pressures of climate, food and health conditions. The present genetic human diversity of the Asian populations is all due to these best adapting individuals, who proved most fit to survive in a given place. It is the tracking down of the ancestry of the human populations, through certain tell-tale signs written in every person’s genes, that has empowered scientists to remarkably establish a link between two geographically separated groups of people. To understand the genetic history of the people living in Asia, over 90 scientists from the Human Genome Organization’s (HUGO’s) Pan-Asian SNP Consortium undertook the human genetic mapping of Southeast Asian (SEA) and East Asian (EA) populations, the findings of which have been published in the December 2009 issue of Science. The hallmark of this human ingenuity is nothing but the tracing of certain ‘marker’ genes that for example, may bestow the individual an advantage of better survival in a particular environment, or a disease-gene marker which could be tracked back in time to discover the human population from where that altered/mutated gene may have originated.
In this unique attempt 1,928 unrelated individuals representing 73 populations from 10 countries and 10 linguistic lineages from mainland China, India, Indonesia, Japan, Malaysia, the Philippines, Singapore, South Korea, Taiwan and Thailand were studied. For establishing genetic differences between two unrelated individuals, scientists basically look at more than three million differences in their genes. Variations at the level of single nucleotides, are commonly referred to as single nucleotide polymorphism (SNP). Therefore, it is the tracking of genetic variations through human migrations that provide clues to evolution of diseases and genetic diversity. Genotyping of more than 50,000 SNPs was done at eight different centres while the filtering of collected data was centralized to maximize the standardization of results. This genetic mapping of people inhabiting different parts of Asia has opened the door to understand the migratory patterns in human history as well as the genetic basis of many diseases afflicting human populations of this region.
This study has revealed that populations from the same linguistic group tend to cluster together, which means that there is considerable relatedness within ethnic/linguistic groups. It has also revealed that there was a south-to-north migration of East Asians, which means that the majority of East Asian gene pool has been derived from Southeast Asia. According to the study, the most recent common ancestors of Asians arrived first in India. Later, some of them migrated to Thailand, and also South to Malaysia, Indonesia, and the Philippines. The first group of settlers must have gone very far south before they settled successfully. These included the Malay Negritos, Philippine Negritos, the East Indonesians, and the early settlers of the Pacific Islands. Later, one or several groups of people migrated North, mixed with previous settlers there resulting in various populations now known as Austronesian, Austro-Asiatic, Tai-Kadai, Hmong-Mien, and Altaic etc. Interestingly, most of the Indian population showed evidence of shared ancestry with European population.

Signifying the implications of this study, nothing can better echo the sentiments of scientists than the words of Professor Samir Brahmachari, former Director General, CSIR: “We have breached political and ideological boundaries to show that the people of Asia are linked by a unifying genetic thread.”

CSIR’s Breakthrough in Baby Food

CSIR’s Breakthrough in Baby Food

{Feature has been uploaded by CSIR (Unit for Science Dissemination), Ministry of Science & Technology, New Delhi}

As a newborn steps into this world with its first cry, the mother’s pivotal role in satisfying her baby’s need for sustenance becomes all too clear. It is breast milk ― a nectar for infants ― that is the best first food as it naturally contains all the components of healthy infant nutrition in correct proportions. It is not only easily digestible but even has properties to promote the development of intestines and brain. A complete food nutritionally, breast milk also equips a baby to fight off infections, which is why there can be no substitute for this unique gift of Nature.
Nonetheless, there are women who are unable to breast feed due to reasons such as lactation failure, insufficient milk secretion, or they suffer from infectious diseases. Such infants have to depend upon ready-foods, available in the market, specially designed for them. Thanks to CSIR scientists at the Central Food Technological Research Institute (CFTRI), Mysore, India today has a flourishing infant food manufacturing industry and does not depend upon the import of foreign infant food brands as it did more than five decades ago.  Prior to 1960, the supply of infant foods meant  a heavy burden on our foreign exchange reserves.
Although hundreds of thousands of parents rely on commercially sold infant foods, most of them are oblivious to the scientific innovation that has gone into designing these baby-friendly products in India. Amul, a baby food based on the CFTRI technology, is a household name in India but alas, not many people are aware of the genesis of this tasty and healthy infant formulation.
Many developed countries produced infant food from cow’s milk, for which standardized production protocols were known. However, as buffalo milk is more readily available in India than cow’s milk, scientists at CFTRI developed a process in late 1950s for the production of infant food from buffalo milk. Later, in 1961, the National Research Development Corporation (NRDC) licensed the process of this indigenous infant food formula to the Kaira District Milk ProducersUnion, at Anand, Gujarat, which produced infant food under the brand name Amul Spray. It was the first time anywhere in the world that baby food was made from buffalo milk on a commercial scale.
Earlier to the development of CFTRI’s formulation, buffalo’s milk, was considered unsuitable for easy digestion by a baby. However, CFTRI technology proved that buffalo’s milk could be turned into a nourishing infant food. This achievement gave a significant boost to the Indian dairy industry, while fulfilling the country’s requirement of having indigenous technology to manufacture infant foods.
The WHO/Food and Agricultural Organization of the United Nations (FAO) Codex Alimentarius Commission, defines infant food as a product "specially manufactured to satisfy the nutritional requirements of infants during the first months of life up to the introduction of appropriate complementary feeding", and is “a product based on milk of cows or other animals or a mixture thereof and/or other ingredients which have been proven to be suitable for infant feeding.

The nutritive value of infant foods, prepared from buffalo milk containing 10%, 12.5% and 15% protein and fortified with DL-methionine has been studied in experiments with albino rats. The average weekly growth rate of rats receiving milk food containing 10% protein, 20% fat and fortified with DL-methionine was of the same order as those obtained with milk foods containing higher percentage of protein. This formula of infant food, prepared from buffalo milk, was considered suitable for feeding infants in place of full cream milk powder in developing countries, at a reasonable cost. It was also found that milk food containing 10% protein but not fortified with DL-methionine promoted significantly less growth.
Normally, the nutrients contained in baby foods provide 400-600 calories and are mostly fortified with appropriate doses of calcium, iron, and vitamins A, D, C, E, B1, B2, B6 and B12 along with folic acid, niacinamide, calcium pantothenate. In addition to infant foods meant for healthy babies, products have also been designed for those with special nutritional requirements, such as babies born prematurely or suffering from allergies. This includes soya-based, hypoallergenic, or lactose-free infant food formulations.
Lactose is the sugar contained in milk, which is broken down to simpler sugars, glucose and galactose, in the body by an enzyme called lactase, which is produced by the cells lining the small intestine. This enzyme, needed to digest lactose, is normally present in children and even adults who consume milk regularly. However, in some persons there is a deficiency of the enzyme lactase that makes them lactose intolerant. A high incidence of lactose intolerance is also observed in older adults. There is a possible genetic link to lactase deficiency, which is why many children are lactose intolerant. Infants born prematurely are more likely to have lactase deficiency because an infant’s lactase levels do not increase until the third trimester of pregnancy. Lactose intolerance makes an infant or adult quite uncomfortable after consuming milk and milk products. The common symptoms include abdominal pain and bloating, gas, diarrhea, and nausea.
Suiting the needs of infants who cannot digest milk easily due to lactose intolerance, CFTRI has developed the technology for the production of low lactose milk by using permeabilized yeast cells or specific enzymes that hydrolyze lactose to glucose and galactose. ‘Lactulose’ containing infant formula has also been developed, which is specially for babies fed on artificial baby foods, as they lack adequate growth of beneficial microflora, which is found in babies fed on mother’s milk.
Not just that. As the baby grows, the nutritional requirements also increase, which at about three months of age need to be supplemented with semi-solid foods. Novel CFTRI technologies have again proved that healthy weaning foods for infants can be manufactured in India. CFTRI has developed novel weaning foods based on malted cereals/millets and germinated green grams.
CFTRI’s pioneering efforts for developing technologies to produce cheap yet nutritionally rich weaning foods, based on protein isolated from edible oilseed meals is commendable. It was way back in 1965 when Shurpalekar and co-workers at CFTRI published a study on the preparation of a weaning food based on whole soy flour, that contained the spray-dried soy protein. This product was fortified with methionine, vitamins and minerals, contained 26% protein and 18% fat. In 1966 Bal-Amul, the first weaning food developed and manufactured in Asia, was launched in India. This soy-fortified weaning food became very popular at that time. Similarly, in early 1970s Narayanaswamy and co-workers at CFTRI developed a method for making whole soy flour in India and created low-cost protein food that was a blend of wheat and soy flours (70:30).
Another product, Bal-Ahar, was a soy-fortified dietary supplement that contained soy flour, cottonseed or peanut flour and dry milk. Designed to replace soy based imported weaning foods, Bal-Ahar was developed as part of a UNESCO project. Many energy foods that are nutritional supplements, developed by CFTRI, have been distributed to the needy in various social welfare projects including disaster relief activities and many nutrition intervention programs of different States.
In yet another achievement, scientists at CFTRI along with their counterparts at the Federal Institute of Industrial Research, Lagos, Nigeria have developed weaning food formulations that are based on malting of sorghum and cowpea. Malting the controlled germinating and drying of a seed ― has been a popular technology for designing supplementary food for babies in the weaning period. For this, the sorghum and cowpea seed are first soaked in water and then allowed to germinate. The so formed sorghum sprouts are dried to about 14% moisture and kilned at 70°C, and later milled and sieved to obtain the malt flour. Cowpea sprouts are split, dehusked, and similarly kilned and milled. To prepare the malted weaning food (MWF), the malted sorghum and cowpea flours are blended in the proportion of 70:30. Scientists have also formulated a precooked weaning food by roller drying a cold water slurry consisting of 70% sorghum flour and 30% cowpea flour.
Formulating weaning foods based on germinated cereals and legumes has a significant nutritional importance as during germination the insoluble protein is transformed into soluble components, and many vitamins and essential amino acids like lysine and tryptophan are known to increase. Besides providing sufficient nutrition to the growing child, such weaning foods are low cost.
Whether it is food for newborns or those with special nutritional needs including infants in the weaning phase who require supplementary food, CFTRI technologies have touched the Indian household in many ways and it shall continue to do so as the baby food industry marches ahead to serve the nation.







Thursday, 22 September 2016

Risorine- A Novel CSIR Drug Curtails TB Treatment by Dr P. Cheena Chawla

Our battle against the disease-causing bugs is endless. Since antiquity scores of infectious diseases caused by bacteria, viruses and fungi have affected millions of people worldwide. Fighting these formidable foes has not been easy as these tiny life forms that cause life threatening diseases in human beings are clever enough to thwart all our attempts made to pin them down. Take, for example, a wide range of antibiotics – the potent tools to kill many harmful bacteria – that are turning ineffective in the wake of development of resistance in microorganisms to these drugs. Moreover, due to the indiscriminate use of antibiotics there is an increasing microbial resistance to many new antibiotics as well.
            To make matters worse, most antibiotics have their well known side effects on the human body. This is particularly a matter of great concern for diseases like tuberculosis for which patients have to take long-term treatment with drugs namely, rifampicin and isoniazid that have many adverse reactions on different organs of the body. In this light, the development of special molecules called ‘bio-enhancers’ is a scientific breakthrough, as bio-enhancers have no drug activity of their own but are uniquely endowed with properties for promoting the biological activity or simply the uptake of other drugs.
            The bountiful Nature is replete with natural products, mainly contained in plant sources, which have played an important role in the development of drugs. Synergism – increase in the action of one biomolecule by another unrelated chemical – is the hallmark of herbal drugs. For example, ‘berberine’ is an anti-microbial alkaloid isolated from Berberis fremontii  that has very weak anti-microbial activity in solution. However, in combination with a compound called 5-Methoxy hydnocarpin (5-MHC) the anti-microbial activity of berberine is increased by 200 folds against the bacterium, Staphylococcus aureus. Similarly, such bioenhancer activity of cow-urine distillate in a composition containing antibiotics and anti-cancer agents is also well known.  Undoubtedly, bioavailability enhancement helps to lower dosage levels and shorten the treatment course.
             In a significant development, Indian Institute of Integrative Medicine (IIIM), Jammu in public private partnership with Cadila Pharmaceutical Ltd, Ahmedabad has released a new drug formulation against tuberculosis called ‘risorine’ that contains reduced dose (200 mg) of rifampicin + isoniazid (300 mg) + piperine (10 mg) found to be bioequivalent to standard rifampicin regimen. Launched in November 2009, this indigenously developed drug formulation could drastically cut short the duration of TB treatment. Risorine has been approved for marketing by Drug Controller General of India after successful completion of all the phased clinical trials.
            The R&D work on developing this formulation was started in the erstwhile Regional Research Laboratory, Jammu now renamed as Indian Institute of Integrative Medicine by Dr. C. K. Atal, former Director, in early 1980s. On scrutinizing a large number of ancient Indian Ayurvedic formulations used in the treatment of a wide range of diseases, it was observed that in a majority of formulations ‘Trikatu’ was used as one of the ingredients. Trikatu is a combination of three herbal products namely Piper nigrum (black pepper) and Piper longum (long pepper) and ginger.
            Concerted research efforts resulted in the isolation of an active alkaloidal molecule called ‘piperine’ from piper species, which was shown to increase the bioavailability of specific drugs. On combining piperine with many common drugs, a reduction of dose of that drug was observed for the same pharmacological effects, without any activity of piperine itself. This is due to enhanced uptake of the drug by body cells, and also because the drug remains available in blood for long durations.
            Popularly known as bioenhancers’, such compounds simply enhance the bioavailability and bio-efficacy of other drugs with which they are combined, without any pharmacological activity of their own at the same dose level. Scientists at IIIM, Jammu tested the bioenhancing activity of piperine on various drugs, which ultimately resulted in designing the risorine formulation useful for the treatment of tuberculosis. The work, now patented, has been documented in various national and international journals particularly in India, Europe and USA.
            The bacterium, Mycobacterium tuberculosis, infects one in three people worldwide and kills about 3 million victims every year on a global scale. Nearly 9 million new TB cases add to the TB burden of our planet annually. TB is a major public health problem in our country as India accounts for one-fifth of the global TB incident cases. Besides this huge burden of TB patients, the cases with multi-drug resistant tuberculosis (MDR-TB) are on the rise as many patients discontinue with the TB drugs, primarily rifampicin and isoniazid, due to long treatment and unpleasant side effects of the drugs.
            Rifampicin has been a first line anti-tubercular drug for a long time. It has been used for treating tuberculosis since 1960s and is known for causing many side effects. Also, the levels of rifampicin in blood decrease over a period of time due to the auto-induction of drug metabolizing enzymes by rifampicin.      In fact, cells of the human body contain on their surface membranes certain proteins called ‘transporter’ proteins that ‘pump’ specific substances out of cells, for being taken away by the blood.             Undoubtedly, these proteins can protect cells from toxic overloads of many substances, but at the same time they can also spoil the efficacy of otherwise beneficial drugs, like rifampicin, by pumping them out of the cells before they can act. One of the most important such ‘pump’ proteins is p-glycoprotein, which is found in the membranes of cells in the intestines, brain, liver, pancreas, kidneys, and other tissues.
            At the molecular level, p

iperine acts by suppressing p-glycoprotein and cytohrome P450 enzymes, which
counteract the metabolism  of rifampicin via these proteins, thus enhancing the oral bioavailability of rifampicin. Piperine also decreases the intestinal production of glucuronic acid, thus allowing more substances to enter the body in active form. This wonder compound thus allows many drugs to enter and remain within their target cells for longer durations.   
            Management of TB with risorine is poised to have remarkable benefits as the use of bioavailability enhancers, in general, not only increase the bioavailability for a drug, but also help reducing the cost of treatment and incidents of drug resistance while minimizing adverse drug reactions. In this new formulation, the rifampicin dose has been reduced from 450 mg to 200 mg along with isoniazid and piperine, with the same pharmacological activity as used earlier. Risorine could even replace the currently used rifampicin used in the 'Directly Observed Treatment Short-course' (DOTS) therapy, run by the Central government in association with different States.
            According to the team of scientists at IIIM, risorine is very safe, effective and economical for the management of tuberculosis. In other words, with use of risorine TB patients would get cured in a shorter span of treatment.  Interestingly, in a multi-centric clinical trial conducted across India in patients with radiologically confirmed diagnosis of pulmonary tuberculosis, more than 90% of the patients treated with risorine were cured of tuberculosis with lesser side effects. This formulation for tackling TB is poised to capture foreign markets like China, Russia and African countries and expects to multiply several times its turnover from this segment.

            A marvel of the plant world and a sure gift to humankind, the black pepper has both culinary and medicinal values. Among its myriad medicinal properties, the one that makes its compound piperine a bioenhancer holds immense promise for making ‘dose economy’ drugs that particularly suit the health needs of people in the developing countries.

A Breakthrough Project of CSIR The Birth of TKDL and Beyond by Dr P. Cheena Chawla

Open your grandmother’s medicine box and you will invariably find it full of herbs or their parts: saunf, ajwain, pepper, haldi, tulsi, Aloe, neem, and the list is endless. Strangely though, you will find that many traditional recipes, for countering a plethora of illnesses, simply work wonders. This knowledge has got passed down several generations only because the unique herbal formulations for treating the human body have given consistent results over the centuries. The ancient Indian wisdom of the usage of thousands of medicinal plants, in unique combinations and definite doses, is truly a blessing for keeping at bay the discomfort of many dreadful diseases.
The sanctity of our traditional knowledge is well established for it is codified in several classical ancient texts in the form of hundreds of thousands of Sanskrit slokas that mention scores of unique formulations of various herbs. This vedic knowledge – a handiwork of our sages and learned forefathers – is a treasure trove of information that unfortunately remained accessible to only a few experts, and long languished in the prison of ignorance of the common masses. Besides, the tribal and indigenous communities have also for long been the custodians of our country’s rich biodiversity. Nonetheless, this enormous traditional wealth, collected over millennia with some of it codified in a large number of old treatises of medicine, is a part of our rich legacy and belongs to India.
In modern times, with global resurgence of interest in herbal medicine, medicinal plants and their products are not just the source of affordable healthcare with minimal side effects, but are also important In terms of international trade and commerce. Realizing the potential of earning huge profits, many multinational pharmaceutical companies began to target the exploitation of traditional knowledge related to medicinal plants. To stop this exploitation, the need to protect the owners of traditional knowledge and provide them their rightful dues stemmed. It thus became imperative to safeguard the IPR on traditional knowledge.
       A new era dawned when a US patent granted for the wound-healing properties of turmeric was challenged successfully by CSIR. In a landmark decision, the United States Patent and Trademark Office (USPTO) revoked it after ascertaining the medicinal use of turmeric in India for centuries. This opened the floodgates for successful fights for the rights to neem and basmati rice, which firmly established the need to document our precious traditional knowledge for shielding it from the assault of wrongful grant of patents. Although these tough fights were won, a lot of time and funds were invested. Cancellation of the patent for turmeric took about two years while it took five years for revoking the patent on the anti-fungal properties of neem.
        It thus became clear that it is possible to revoke the grant of wrong patents at international level and also exposed the fact that relevant information on traditional knowledge was not available to International patent examiners in a retrievable format. The need to systematize the documentation of knowledge existing in the public domain, on various traditional systems of medicine, thus assumed great significance for preventing the misuse of this knowledge through non-original inventions.
While considering the patentability of any subject matter, the patent examiners search available resources for non-patent and patent literature. Although patent literature is available in many databases that can be easily retrieved, non-patent literature normally appeared scattered. Thus arose the challenge to create non-patent literature databases, containing information on traditional knowledge that was easily accessible. 

            In this endeavour, CSIR was on the forefront as a collaborative Project – the Traditional Knowledge Digital Library (TKDL) – was initiated between the National Institute of Science Communication & Information Resources (NISCAIR) and the Department of Indian System of the Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH), erstwhile Department of Indian System of Medicine and Homoeopathy (ISM&H), Ministry of Health & Family Welfare. The MoU for this Project was signed on June 6, 2001.
       It all, however, started in June 1999 when the need for creating Traditional Knowledge databases was realized by the Standing Committee on Information Technology (SCIT) of World Intellectual Property Organization (WIPO), under the Chairmanship of Dr. R. A. Mashelkar, the then Director General of CSIR, India. A few months later, an Approach Paper on setting up of TKDL was prepared by Mr. V. K. Gupta, the then Senior Technical Director, National Informatics Centre, the former Director, NISCAIR. This paper was submitted to SCIT, WIPO the same year.
         In January 2000, an inter-disciplinary Task Force on TKDL, consisting of experts from the then Department of ISM&H, Central Council of Research in Ayurveda & Siddha (CCRAS), Banaras Hindu University (BHU), National Informatics Centre (NIC), and Controller General of Patents Designs & Trade Marks (CGPDTM) was set up under the Chairmanship of Mr. V. K. Gupta. In January 2001, the Cabinet Committee of Economic Affairs (CCEA’s) finally gave approval on the TKDL Project – a triumph for the entire TKDL team.
           Implemented at CSIR, the TKDL Project comprises an inter-disciplinary team of Traditional Medicine (Ayurveda, Unani, Siddha and Yoga) experts, patent examiners, IT experts, scientists and technical officers. The focus of this Project has been to create database on the codified traditional knowledge on Indian Systems of Medicine. For example, for documenting knowledge in Ayurveda, the available information in public domain was first searched, sifted and collated. The coded information lying dormant in the Sanskrit slokas was understood and converted into structured language using the specially created Traditional Knowledge Resource Classification (TKRC) and saved in the database by experts in the field. The saved information can be read in five different languages (English, German, French, Japanese and Spanish) and is simple to comprehend. The TKDL software is special for it does smart translation, instead of mere transliteration, of Ayurvedic descriptions from traditional terminology into modern terminology.
         Several thousands of herbal formulations from various Ayurvedic texts have been thus transcribed in patent application format. Similarly, traditional knowledge available in public domain, related to Unani, Siddha and Yoga, has also been converted to the user-friendly digitized format that is easily understandable. This TKDL database thus acts as a strong bridge between the traditional knowledge available in public domain and the patent examiners in various patent offices. 
       In yet another achievement in February 2002, about 200 subgroups on Traditional Knowledge on medicinal plants were included against the existing few besides the linking of TKRC to the international Patent Classification (IPC). Several specialized subgroups were later included as the Project advanced. A demo CD containing a sample of 500 formulations was released in October, 2003 by the then Hon’ble Union Minister of Human Resource Development, Science & Technology, and Ocean Development at NISCAIR. Three years later, in a landmark achievement, the Cabinet Committee on Economic Affairs gave its approval on the access to TKDL database to International Patent Offices.
       In the year 2009 access to TKDL database was given first to the European Patent office, and then to the Indian Patent Office (CGPDTM), German Patent and Trademark Office (DPMA) and more recently to the USPTO (CSIR News, Vol. 59, 15 & 30 December 2009) under the respective TKDL Access Agreements. This allows the various patent offices access to about two lakh medicinal formulations on Ayurveda, Unani and Siddha, comprising a whopping 30 million pages!  Following this, there have been innumerable cases of withdrawal of patent applications, where the subject matter was not considered to be original work due to TKDL prior art evidence. With a cost of about 1.18 crore, the TKDL Project — a breakthrough that benefits the owners of traditional knowledge from theft of their knowledge — is a classic example of integrating the enormous capabilities of Information technology for creating mechanisms of effective access and retrieval of the rich traditional knowledge on medicinal plants collected over millennia, which in addition, has opened up new possibilities for further research.